Breast neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Breast neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer https://clinicaltrials.eu/trial/study-of-oral-thero2-01s22-with-anti-her2-therapy-in-patients-with-metastatic-breast-cancer/ Wed, 29 Apr 2026 15:06:22 +0000 https://clinicaltrials.eu/trial/study-of-oral-thero2-01s22-with-anti-her2-therapy-in-patients-with-metastatic-breast-cancer/ This study focuses on patients with HER2-positive metastatic breast cancer. The research evaluates a new treatment approach that combines standard anti-HER2 therapy with an experimental medication called TherO2-01S22. The standard treatment includes established medications such as trastuzumab, pertuzumab, docetaxel, paclitaxel, and vinorelbine.

The main purpose of this research is to determine if adding TherO2-01S22 syrup to the standard anti-HER2 treatment can improve treatment outcomes for patients with metastatic breast cancer. During the study, participants will receive either TherO2-01S22 or placebo in addition to their regular cancer treatment.

The treatment period lasts up to 18 months, during which patients will receive medication through both oral intake and intravenous infusion. Throughout the study, doctors will monitor patients’ response to treatment, overall health status, and any potential side effects. Regular assessments will include heart function monitoring and quality of life evaluations.

]]> Study on the Effects of Selumetinib, Bicalutamide, and Olaparib in Patients with Metastatic Breast Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-selumetinib-bicalutamide-and-olaparib-in-patients-with-metastatic-breast-cancer/ Wed, 29 Apr 2026 14:57:44 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-selumetinib-bicalutamide-and-olaparib-in-patients-with-metastatic-breast-cancer/ This clinical trial is focused on studying the effectiveness of treatments for metastatic breast cancer, which is a type of breast cancer that has spread to other parts of the body. The study will use a combination of medications, including Selumetinib, Casodex (which contains the active substance Bicalutamide), and Olaparib. These medications are taken orally and are designed to target specific pathways in cancer cells to stop their growth. Selumetinib is a type of medication known as a kinase inhibitor, Casodex is an antiandrogen, and Olaparib is a PARP inhibitor.

The purpose of the study is to compare how long patients can live without their cancer getting worse when treated with these medications compared to standard chemotherapy. Participants will be randomly assigned to receive either the experimental treatment or a standard chemotherapy regimen. Some participants may receive a placebo. The study will last for up to 12 months, during which time participants will take the study medications and attend regular check-ups to monitor their health and the progression of their cancer.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI to evaluate the size and spread of their cancer. The study aims to provide valuable information on whether these new treatment combinations can improve outcomes for patients with metastatic breast cancer. The ultimate goal is to find more effective treatment options that can help patients live longer and with a better quality of life.

]]> Study Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment https://clinicaltrials.eu/trial/study-comparing-abemaciclib-and-fulvestrant-with-placebo-and-fulvestrant-for-patients-with-advanced-or-metastatic-breast-cancer-after-previous-treatment/ Wed, 29 Apr 2026 14:56:45 +0000 https://clinicaltrials.eu/trial/study-comparing-abemaciclib-and-fulvestrant-with-placebo-and-fulvestrant-for-patients-with-advanced-or-metastatic-breast-cancer-after-previous-treatment/ This clinical trial is focused on studying a type of breast cancer known as HR-positive, HER2-negative advanced or metastatic breast cancer. This type of cancer is characterized by the presence of hormone receptors (HR) and the absence of a protein called HER2. The study is designed to evaluate the effectiveness of a treatment combination involving two medications: abemaciclib and fulvestrant. Abemaciclib is a medication that works by inhibiting certain proteins involved in cancer cell growth, while fulvestrant is a hormone therapy that blocks the effects of estrogen on cancer cells. The trial will compare the effects of using both abemaciclib and fulvestrant together against using a placebo with fulvestrant.

The purpose of the study is to determine how well the combination of abemaciclib and fulvestrant works in treating patients who have already been treated with a type of medication called a CDK4/6 inhibitor and hormone therapy. Participants in the study will be randomly assigned to receive either the combination of abemaciclib and fulvestrant or a placebo with fulvestrant. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, which is known as a double-blind study.

Throughout the study, participants will receive regular check-ups and monitoring to assess the progression of their cancer and any side effects from the treatment. The study aims to provide valuable information on whether the combination of abemaciclib and fulvestrant can help improve outcomes for patients with this specific type of breast cancer. The trial is expected to continue for a period of time to gather sufficient data on the treatment’s effectiveness and safety.

]]>